News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
853,598 Results
Type
Article (77782)
Company Profile (721)
Press Release (775073)
Multimedia
Podcasts (231)
Webinars (35)
Section
Business (227600)
Career Advice (3754)
Deals (39456)
Drug Delivery (177)
Drug Development (89863)
Employer Resources (207)
FDA (18270)
Job Trends (17240)
News (388836)
Policy (39001)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (3052)
Academic (1)
Accelerated approval (56)
ADA (49)
Adcomms (40)
Allergies (198)
Alliances (56052)
ALS (235)
Alzheimer's disease (1967)
Antibody-drug conjugate (ADC) (552)
Approvals (18612)
Artificial intelligence (814)
ASCO (344)
Autoimmune disease (361)
Automation (63)
Bankruptcy (404)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (248)
Biotechnology (437)
Bladder cancer (209)
Brain cancer (85)
Breast cancer (835)
Cancer (6546)
Cardiovascular disease (552)
Career advice (3231)
Career pathing (52)
CAR-T (384)
CDC (76)
Celiac Disease (3)
Cell therapy (1044)
Cervical cancer (54)
Clinical research (77597)
Collaboration (2371)
Company closure (7)
Compensation (1512)
Complete response letters (106)
COVID-19 (3040)
CRISPR (124)
C-suite (1285)
Cystic fibrosis (167)
Data (8690)
Decentralized trials (3)
Denatured (89)
Depression (193)
Dermatology (97)
Diabetes (698)
Diagnostics (7588)
Digital health (67)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (394)
Drug pricing (244)
Drug shortages (39)
Duchenne muscular dystrophy (318)
Earnings (99213)
Editorial (78)
Employer branding (25)
Employer resources (174)
Events (137374)
Executive appointments (1193)
FDA (22326)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (36)
Funding (1934)
Gene editing (269)
Generative AI (78)
Gene therapy (835)
GLP-1 (1282)
Government (5511)
Grass and pollen (8)
Guidances (420)
Healthcare (21240)
Hematology (197)
HIV (94)
Huntington's disease (64)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (352)
Immuno-oncology (116)
Indications (206)
Infectious disease (3436)
Inflammatory bowel disease (242)
Inflation Reduction Act (17)
Influenza (147)
Intellectual property (321)
Interviews (736)
IPO (17901)
IRA (61)
Job creations (4963)
Job search strategy (2602)
JPM (73)
Kidney cancer (22)
Labor market (122)
Layoffs (682)
Leadership (53)
Legal (9969)
Liver cancer (111)
Longevity (36)
Lung cancer (871)
Lymphoma (470)
Machine learning (64)
Management (66)
Manufacturing (1201)
MASH (226)
Medical device (15252)
Medtech (15412)
Mergers & acquisitions (22855)
Metabolic disorders (1814)
mRNA (265)
Multiple sclerosis (204)
NASH (24)
Neurodegenerative disease (506)
Neuropsychiatric disorders (126)
Neuroscience (3706)
Neurotech (1)
NextGen: Class of 2026 (7671)
Non-profit (5144)
Now hiring (80)
Obesity (869)
Opinion (374)
Ovarian cancer (242)
Pain (284)
Pancreatic cancer (352)
Parkinson's disease (415)
Partnered (36)
Patents (647)
Patient recruitment (763)
Peanut (70)
People (66560)
Pharmaceutical (125)
Pharmacy benefit managers (37)
Phase 1 (24009)
Phase 2 (33836)
Phase 3 (25481)
Pipeline (9755)
Policy (397)
Postmarket research (3281)
Preclinical (10593)
Press Release (72)
Prostate cancer (345)
Psychedelics (68)
Radiopharmaceuticals (372)
Rare diseases (1262)
Real estate (7199)
Recruiting (81)
Regulatory (29620)
Reports (75)
Research institute (2764)
Resumes & cover letters (585)
Rett syndrome (43)
RNA editing (29)
RSV (98)
Schizophrenia (196)
Series A (327)
Series B (237)
Service/supplier (25)
Sickle cell disease (127)
Special edition (32)
Spinal muscular atrophy (189)
Sponsored (55)
Startups (4271)
State (2)
Stomach cancer (21)
Supply chain (144)
Tariffs (104)
The Weekly (139)
Vaccines (1303)
Venture capital (134)
Weight loss (597)
Women's health (141)
Worklife (24)
Date
Today (34)
Last 7 days (640)
Last 30 days (3067)
Last 365 days (32647)
2026 (16074)
2025 (32532)
2024 (37882)
2023 (42563)
2022 (53926)
2021 (58718)
2020 (57660)
2019 (51300)
2018 (39078)
2017 (36819)
2016 (37717)
2015 (43722)
2014 (38362)
2013 (34395)
2012 (36328)
2011 (36369)
2010 (35789)
Location
Africa (1225)
Alabama (102)
Alaska (7)
Arizona (379)
Arkansas (16)
Asia (50796)
Australia (8710)
California (14362)
Canada (3986)
China (1571)
Colorado (620)
Connecticut (638)
Delaware (440)
Europe (115446)
Florida (2132)
Georgia (466)
Hawaii (4)
Idaho (69)
Illinois (1227)
India (101)
Indiana (663)
Iowa (25)
Japan (593)
Kansas (141)
Kentucky (57)
Louisiana (64)
Maine (89)
Maryland (1739)
Massachusetts (10501)
Michigan (409)
Minnesota (799)
Mississippi (7)
Missouri (164)
Montana (37)
Nebraska (30)
Nevada (153)
New Hampshire (91)
New Jersey (3811)
New Mexico (35)
New York (3774)
North Carolina (1928)
North Dakota (11)
Northern California (7152)
Ohio (446)
Oklahoma (27)
Oregon (53)
Pennsylvania (2823)
Puerto Rico (30)
Rhode Island (54)
South America (1583)
South Carolina (88)
South Dakota (2)
Southern California (5639)
Tennessee (227)
Texas (2320)
United States (51270)
Utah (426)
Vermont (1)
Virginia (365)
Washington D.C. (89)
Washington State (1177)
West Virginia (4)
Wisconsin (158)
Wyoming (2)
853,598 Results for "jiangsu hengrui medicine co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.
May 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
May 12, 2026
·
7 min read
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
February 10, 2026
·
1 min read
·
Tristan Manalac
Business
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).
February 7, 2024
·
7 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
June 7, 2026
·
13 min read
Press Releases
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
June 1, 2026
·
5 min read
Press Releases
FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity
May 4, 2026
·
4 min read
China
Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+
Hengrui Pharmaceuticals has been busy this year, signing a nearly $2 billion cardio contract with Merck in March and a 12-asset agreement with GSK in July worth up to $12 billion.
September 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
April 22, 2026
·
1 min read
1 of 85,360
Next
